DexCom (DXCM) Stock Forecast, Price Target & Predictions
DXCM Stock Forecast
DexCom stock forecast is as follows: an average price target of $81.36 (represents a 8.13% upside from DXCM’s last price of $75.24) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.
DXCM Price Target
The average price target for DexCom (DXCM) is $81.36 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $146.00 to $28.13. This represents a potential 8.13% upside from DXCM's last price of $75.24.
DXCM Analyst Ratings
According to 13 Wall Street analysts, DexCom's rating consensus is 'Buy'. The analyst rating breakdown for DXCM stock is 1 'Strong Buy' (7.69%), 10 'Buy' (76.92%), 2 'Hold' (15.38%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
DexCom Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 08, 2024 | Shagun Singh | RBC Capital | $120.00 | $68.62 | 74.88% | 59.49% |
| Aug 22, 2024 | Mathew Blackman | Stifel Nicolaus | $100.00 | $72.28 | 38.35% | 32.91% |
| Aug 16, 2024 | Shagun Singh | RBC Capital | $130.00 | $72.36 | 79.66% | 72.78% |
| Jul 29, 2024 | Matt Miksic | Barclays | $113.00 | $64.00 | 76.56% | 50.19% |
| Jul 26, 2024 | Steven Lichtman | Oppenheimer | $115.00 | $107.85 | 6.63% | 52.84% |
| Jul 26, 2024 | Matt O\'Brien | Piper Sandler | $90.00 | $63.22 | 42.36% | 19.62% |
| Jul 26, 2024 | William Plovanic | Canaccord Genuity | $89.00 | $107.85 | -17.48% | 18.29% |
| Jul 26, 2024 | Shagun Singh | RBC Capital | $145.00 | $63.55 | 128.17% | 92.72% |
| Jul 12, 2024 | Mathew Blackman | Stifel Nicolaus | $132.00 | $112.66 | 17.17% | 75.44% |
| Jun 03, 2024 | Steven Lichtman | Oppenheimer | $150.00 | $115.23 | 30.17% | 99.36% |
The latest DexCom stock forecast, released on Oct 08, 2024 by Shagun Singh from RBC Capital, set a price target of $120.00, which represents a 74.88% increase from the stock price at the time of the forecast ($68.62), and a 59.49% increase from DXCM last price ($75.24).
DexCom Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 12 |
| Avg Price Target | - | $110.00 | $123.25 |
| Last Closing Price | $75.24 | $75.24 | $75.24 |
| Upside/Downside | -100.00% | 46.20% | 63.81% |
In the current month, the average price target of DexCom stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to DexCom's last price of $75.24. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 22, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 08, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Sep 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 26, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 23, 2024 | William Blair | Buy | Buy | Hold |
| Aug 23, 2024 | Wells Fargo | Underperform | Underperform | Hold |
| Aug 16, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 30, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
| Jul 29, 2024 | Wells Fargo | Underperform | Underperform | Hold |
| Jul 29, 2024 | William Blair | Buy | Buy | Hold |
DexCom's last stock rating was published by Piper Sandler on Oct 22, 2024. The company gave DXCM a "Overweight" rating, the same as its previous rate.
DexCom Financial Forecast
DexCom Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $1.03B | $975.00M | $871.30M | $741.50M | $815.20M | $769.60M | $696.20M | $628.80M | $698.20M | $650.20M | $595.10M | $505.00M | $568.90M | $500.90M | $451.80M | $405.10M | $462.80M | $396.30M |
| Avg Forecast | $1.44B | $1.34B | $1.29B | $1.19B | $1.27B | $1.17B | $1.13B | $1.03B | $1.10B | $990.44M | $1.04B | $909.93M | $1.02B | $939.64M | $841.16M | $720.71M | $810.10M | $751.80M | $697.50M | $623.87M | $697.47M | $618.65M | $551.67M | $486.59M | $553.01M | $500.90M | $416.62M | $358.55M | $441.02M | $347.89M |
| High Forecast | $1.48B | $1.38B | $1.33B | $1.22B | $1.30B | $1.21B | $1.16B | $1.06B | $1.11B | $991.10M | $1.04B | $909.93M | $1.04B | $948.40M | $865.01M | $741.14M | $833.06M | $751.80M | $697.50M | $623.87M | $697.47M | $618.65M | $551.67M | $486.59M | $553.01M | $500.90M | $416.62M | $358.55M | $441.02M | $347.89M |
| Low Forecast | $1.40B | $1.31B | $1.26B | $1.16B | $1.24B | $1.15B | $1.11B | $1.01B | $1.08B | $989.78M | $1.04B | $909.93M | $991.22M | $931.05M | $821.20M | $703.60M | $790.87M | $751.80M | $697.50M | $623.87M | $697.47M | $618.65M | $551.67M | $486.59M | $553.01M | $500.90M | $416.62M | $358.55M | $441.02M | $347.89M |
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 14 | 9 | 1 | 1 | 3 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.04% | 1.04% | 1.03% | 1.01% | 1.02% | 1.00% | 1.01% | 1.00% | 1.05% | 1.08% | 1.04% | 1.03% | 1.00% | 1.08% | 1.13% | 1.05% | 1.14% |
DexCom's average Quarter revenue forecast for Mar 24 based on 1 analysts is $909.93M, with a low forecast of $909.93M, and a high forecast of $909.93M. DXCM's average Quarter revenue forecast represents a -12.04% decrease compared to the company's last Quarter revenue of $1.03B (Dec 23).
DexCom EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 14 | 9 | 1 | 1 | 3 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $303.60M | $207.20M | $128.10M | $110.70M | $139.70M | $190.00M | $123.60M | $78.30M | $44.30M | $141.30M | $125.40M | $66.90M | $126.30M | $117.90M | $81.80M | $50.80M | $123.90M | $73.80M |
| Avg Forecast | $270.58M | $252.45M | $243.37M | $223.60M | $238.92M | $221.14M | $213.27M | $194.45M | $206.41M | $186.51M | $195.31M | $131.18M | $191.19M | $176.94M | $158.40M | $119.26M | $58.93M | $123.25M | $114.35M | $108.42M | $114.35M | $101.42M | $90.44M | $60.21M | $90.66M | $82.12M | $68.30M | $58.06M | $72.30M | $57.03M |
| High Forecast | $278.25M | $259.60M | $250.27M | $229.93M | $245.69M | $227.41M | $219.32M | $200.12M | $208.28M | $186.63M | $195.31M | $157.42M | $196.61M | $178.59M | $162.89M | $143.11M | $70.72M | $123.25M | $114.35M | $130.10M | $114.35M | $101.42M | $90.44M | $72.25M | $90.66M | $82.12M | $68.30M | $69.67M | $72.30M | $57.03M |
| Low Forecast | $264.16M | $246.46M | $237.60M | $218.29M | $233.25M | $215.89M | $208.21M | $190.68M | $202.65M | $186.38M | $195.31M | $104.95M | $186.65M | $175.32M | $154.64M | $95.41M | $47.14M | $123.25M | $114.35M | $86.73M | $114.35M | $101.42M | $90.44M | $48.17M | $90.66M | $82.12M | $68.30M | $46.45M | $72.30M | $57.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.59% | 1.17% | 0.81% | 0.93% | 2.37% | 1.54% | 1.08% | 0.72% | 0.39% | 1.39% | 1.39% | 1.11% | 1.39% | 1.44% | 1.20% | 0.88% | 1.71% | 1.29% |
1 analysts predict DXCM's average Quarter EBITDA for Mar 24 to be $131.18M, with a high of $157.42M and a low of $104.95M. This is -56.79% lower than DexCom's previous annual EBITDA (Dec 23) of $303.60M.
DexCom Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 14 | 9 | 1 | 1 | 3 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $256.30M | $120.70M | $115.90M | $48.60M | $91.80M | $101.20M | $50.90M | $97.30M | $-19.40M | $70.90M | $62.90M | $40.30M | $355.20M | $72.20M | $46.30M | $19.90M | $92.70M | $45.80M |
| Avg Forecast | $309.91M | $267.35M | $237.38M | $188.45M | $253.45M | $221.50M | $198.70M | $159.40M | $212.87M | $178.35M | $158.40M | $163.01M | $176.68M | $139.75M | $92.64M | $148.20M | $-25.81M | $101.91M | $76.45M | $134.72M | $90.82M | $67.66M | $46.25M | $36.27M | $96.72M | $66.79M | $35.08M | $22.74M | $77.36M | $20.85M |
| High Forecast | $321.33M | $277.20M | $246.13M | $195.40M | $262.79M | $229.66M | $206.03M | $193.86M | $229.25M | $178.40M | $158.43M | $195.62M | $189.01M | $189.07M | $96.05M | $177.83M | $-20.65M | $101.91M | $76.45M | $161.67M | $90.82M | $67.66M | $46.25M | $43.52M | $96.72M | $66.79M | $35.08M | $27.29M | $77.36M | $20.85M |
| Low Forecast | $300.35M | $259.10M | $230.06M | $182.64M | $245.63M | $214.66M | $192.58M | $129.24M | $196.50M | $178.31M | $158.37M | $130.41M | $160.24M | $106.87M | $89.78M | $118.56M | $-30.97M | $101.91M | $76.45M | $107.78M | $90.82M | $67.66M | $46.25M | $29.02M | $96.72M | $66.79M | $35.08M | $18.19M | $77.36M | $20.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.45% | 0.86% | 1.25% | 0.33% | -3.56% | 0.99% | 0.67% | 0.72% | -0.21% | 1.05% | 1.36% | 1.11% | 3.67% | 1.08% | 1.32% | 0.88% | 1.20% | 2.20% |
DexCom's average Quarter net income forecast for Mar 24 is $163.01M, with a range of $130.41M to $195.62M. DXCM's average Quarter net income forecast represents a -36.40% decrease compared to the company's last Quarter net income of $256.30M (Dec 23).
DexCom SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 14 | 9 | 1 | 1 | 3 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $308.80M | $284.70M | $297.30M | $294.60M | $297.80M | $234.60M | $248.90M | $220.90M | $235.10M | $199.80M | $187.00M | $188.60M | $175.90M | $158.60M | $136.40M | $149.80M | $129.00M | $124.20M |
| Avg Forecast | $480.95M | $448.72M | $432.59M | $397.43M | $424.67M | $393.07M | $379.09M | $345.64M | $366.88M | $331.51M | $347.16M | $370.09M | $339.83M | $314.51M | $281.55M | $336.45M | $312.74M | $251.64M | $233.46M | $305.86M | $233.45M | $207.07M | $184.65M | $169.74M | $185.10M | $167.66M | $139.45M | $171.20M | $147.61M | $116.44M |
| High Forecast | $494.58M | $461.44M | $444.85M | $408.70M | $436.71M | $404.22M | $389.84M | $355.70M | $370.22M | $331.73M | $347.16M | $444.11M | $349.47M | $317.44M | $289.53M | $403.74M | $375.29M | $251.64M | $233.46M | $367.03M | $233.45M | $207.07M | $184.65M | $203.69M | $185.10M | $167.66M | $139.45M | $205.44M | $147.61M | $116.44M |
| Low Forecast | $469.53M | $438.07M | $422.32M | $388.00M | $414.59M | $383.75M | $370.09M | $338.92M | $360.21M | $331.29M | $347.16M | $296.07M | $331.77M | $311.63M | $274.86M | $269.16M | $250.19M | $251.64M | $233.46M | $244.69M | $233.45M | $207.07M | $184.65M | $135.79M | $185.10M | $167.66M | $139.45M | $136.96M | $147.61M | $116.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.91% | 1.06% | 0.88% | 0.95% | 0.93% | 1.07% | 0.72% | 1.01% | 0.96% | 1.01% | 1.11% | 0.95% | 0.95% | 0.98% | 0.88% | 0.87% | 1.07% |
DexCom's average Quarter SG&A projection for Mar 24 is $370.09M, based on 1 Wall Street analysts, with a range of $296.07M to $444.11M. The forecast indicates a 19.85% rise compared to DXCM last annual SG&A of $308.80M (Dec 23).
DexCom EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 14 | 9 | 1 | 1 | 3 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.31 | $0.30 | $0.13 | $0.24 | $0.26 | $0.13 | $0.25 | $-0.05 | $0.18 | $0.16 | $0.10 | $0.23 | $0.19 | $0.12 | $0.06 | $0.25 | $0.13 |
| Avg Forecast | $0.76 | $0.65 | $0.58 | $0.46 | $0.62 | $0.54 | $0.48 | $0.39 | $0.52 | $0.43 | $0.39 | $0.27 | $0.43 | $0.34 | $0.23 | $0.15 | $0.27 | $0.24 | $0.18 | $0.13 | $0.22 | $0.16 | $0.11 | $0.08 | $0.23 | $0.16 | $0.08 | $0.04 | $0.19 | $0.05 |
| High Forecast | $0.78 | $0.68 | $0.60 | $0.48 | $0.64 | $0.56 | $0.50 | $0.47 | $0.56 | $0.43 | $0.39 | $0.27 | $0.46 | $0.46 | $0.23 | $0.15 | $0.28 | $0.24 | $0.18 | $0.13 | $0.22 | $0.16 | $0.11 | $0.08 | $0.23 | $0.16 | $0.08 | $0.04 | $0.19 | $0.05 |
| Low Forecast | $0.73 | $0.63 | $0.56 | $0.45 | $0.60 | $0.52 | $0.47 | $0.32 | $0.48 | $0.43 | $0.39 | $0.27 | $0.39 | $0.26 | $0.22 | $0.14 | $0.26 | $0.24 | $0.18 | $0.13 | $0.22 | $0.16 | $0.11 | $0.08 | $0.23 | $0.16 | $0.08 | $0.04 | $0.19 | $0.05 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 1.33% | 0.89% | 0.88% | 1.06% | 0.71% | 1.91% | -0.23% | 1.12% | 1.46% | 1.36% | 1.00% | 1.17% | 1.46% | 1.47% | 1.36% | 2.50% |
According to 3 Wall Street analysts, DexCom's projected average Quarter EPS for Dec 23 is $0.43, with a low estimate of $0.39 and a high estimate of $0.46. This represents a 38.94% increase compared to DXCM previous annual EPS of $0.31 (Sep 23).
DexCom Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TNDM | Tandem Diabetes Care | $30.15 | $79.05 | 162.19% | Buy |
| IART | Integra LifeSciences | $22.93 | $43.00 | 87.53% | Sell |
| INMD | InMode | $18.24 | $27.50 | 50.77% | Hold |
| INSP | Inspire Medical Systems | $184.77 | $239.55 | 29.65% | Buy |
| MDT | Medtronic | $84.11 | $107.91 | 28.30% | Hold |
| EW | Edwards Lifesciences | $69.54 | $88.04 | 26.60% | Buy |
| ZBH | Zimmer Biomet | $109.27 | $133.78 | 22.43% | Hold |
| ABT | Abbott Laboratories | $115.93 | $126.45 | 9.07% | Buy |
| DXCM | DexCom | $75.24 | $81.36 | 8.13% | Buy |
| PODD | Insulet | $266.58 | $274.00 | 2.78% | Buy |
| PEN | Penumbra | $239.20 | $224.85 | -6.00% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |